Susquehanna International Group’s Cullinan Oncology CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$834K Buy
58,700
+7,800
+15% +$100K ﹤0.01% 8373
2025
Q4
$527K Buy
+50,900
New +$459K ﹤0.01% 8664
2025
Q3
Sell
-171,100
Closed -$1.29M 12527
2025
Q2
$1.29M Buy
+171,100
New +$1.37M ﹤0.01% 6795
2023
Q4
Sell
-10,200
Closed -$92.3K 12422
2023
Q3
$92.3K Sell
10,200
-23,000
-69% -$240K ﹤0.01% 10985
2023
Q2
$357K Buy
+33,200
New +$353K ﹤0.01% 9080

Other funds holding CGEM

Susquehanna International Group's CGEM Position: Q1 2026 in Review

Susquehanna International Group increased its Cullinan Oncology (CGEM) stake by 19% in Q1 2026, buying an estimated $97.1K and bringing the position to 47,377 shares worth $673K. The position accounts for ﹤0.01% of the portfolio, ranked #8895.

Susquehanna International Group first reported a position in CGEM in Q4 2021 and has held it in 16 quarters since. The position peaked at $978K in Q2 2025. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Susquehanna International Group held 47,377 shares of Cullinan Oncology worth $673K as of Q1 2026.
  • Susquehanna International Group bought 7,555 Cullinan Oncology shares in Q1 2026, an estimated $97.1K.
  • Cullinan Oncology made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8895 holding.
  • Susquehanna International Group first reported a position in Cullinan Oncology in Q4 2021 and has held it in 16 quarters since.
  • Susquehanna International Group's Cullinan Oncology position peaked at $978K in Q2 2025.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.